by Didier | Nov 17, 2017 | News
This article focuses on the repercussions of scheduling NPS as they emerge on the “legal” market. Particularly U-49900, a synthetic opioid that is an analogue of U-47700 (which is itself an analog of an earlier now-banned opioid: AH-7921) It seems... by Didier | Nov 6, 2017 | News
This article describes the identification and characterization of 2-(2-(4-chlorophenyl)acetamido)-3-methylbutanamide, a putative new psychoactive substance, through GC/MS, LC/MS, NMR, FTIR, UV, Single-crystal X-ray diffraction, and NMR. ... by Didier | Nov 2, 2017 | News
This article explores the presence of tryptamines classified as NPS among the substances delivered for analysis to a harm-reduction organization, to describe the substances found in the samples after analysis, and to compare analytical results of regulated vs.... by Didier | Oct 30, 2017 | News
This article presents results of the analysis of 3 NPS: clephedrone (4-CMC), 4-chloroethcathinone (4-CEC), and brephedrone (4-BMC) on recreational drug markets and a systematic review of all the available information concerning these substances. It presents the... by Didier | Oct 25, 2017 | News
This article describes the misrepresentation of LSD at Portugal’s Boom Festival 2014 and the prevention of unintentional consumption of DOx and 25x-NBOMe among LSD consumers attending a drug-checking service. We found that the majority of service users who... 